Objectives: To evaluate, using Monte Carlo simulation, the pharmacodynamics (PD) of empirical antibiotic monotherapies for serious infections consistent with Canadian intensive care unit (ICU) surveillance data.
Introduction
The selection of appropriate empirical antibiotic therapies for high-risk patients such as those in the intensive care unit (ICU) can improve clinical outcomes including survival. In addition to in vitro susceptibility, 'appropriate' antibiotic therapy includes the administration of dosing regimens that optimize pharmacodynamics (PD). 1 -3 In vivo PD are determined by achievable free (f) or unbound antibiotic concentrations at the site of infection and antibacterial potency or activity against target pathogens (e.g. MIC, MBC). PD indices incorporating these variables such as fC max /MIC (highest free concentration divided by the MIC), % fT . MIC (percentage of time free concentrations exceed the MIC) and fAUC/MIC (area under the free concentration-time curve over 24 h divided by the MIC) can be important surrogate markers for microbiological and clinical response. Generally, fC max /MIC is most relevant for the aminoglycosides, % fT . MIC for the penicillins, cephalosporins and carbapenems, and fAUC/ MIC for the fluoroquinolones and vancomycin. Studies that characterize antibiotic PD are important in selecting dosing regimens with a high probability of target attainment.
The translation of in vivo antibiotic PD to the patient setting is complicated by numerous confounding variables. Important considerations in selecting appropriate therapy for an ICU population, for example, include factors related to the patient (e.g. age, body weight, renal function, underlying illnesses), infectious process (e.g. pathogen, site of infection, severity) and antibiotic (e.g. MIC, pharmacokinetics, PD). 4 -6 Robust analyses using Monte Carlo simulation (MCS) can assist in evaluating antibiotic PD and target attainment by constructing populations with specified demographics, relevant infection profiles and individualized antibiotic pharmacokinetics. Such investigations can contribute significantly to identifying optimal antibiotic selection, in addition to dosing regimens and MIC breakpoints for new and existing agents. 7 -10 Our goal was to evaluate, using MCS methods, the PD of empirical antibiotic monotherapy with meropenem, piperacillin/ tazobactam, cefepime and ceftobiprole for serious infections consistent with Canadian ICU surveillance data from 2005 to 2008, inclusive.
Methods

MCS methods in SYSTAT
w (version 12) were used to construct cohorts of 5000 simulated study subjects with an age of 55+11 years (range 19 -102 years), body weight of 70+10 kg (range 45 -95 kg) and uniform distribution of creatinine clearance (CL CR ) from 60 to 120 mL/min/1.73 m 2 . For validation, simulations were repeated using different seeds and sample sizes up to 20 000 subjects.
Potential empirical monotherapies used in Canadian ICUs including a carbapenem (i.e. meropenem), extended-spectrum penicillin/b-lactamase inhibitor (i.e. piperacillin/tazobactam) and broad-spectrum cephalosporin (i.e. cefepime) were tested along with a novel broad-spectrum cephalosporin, ceftobiprole, active against methicillin-resistant Staphylococcus aureus (MRSA). The latter was licensed in Canada in 2008 with indications for complicated skin and skin-structure infections. For each antibiotic, the manufacturer's standard and highest recommended doses as per the product monograph were tested (Table 1 ) (Health Canada, Drug Product Database Online Query at http://webprod.hc-sc.gc.ca/dpd-bdpp/ index-eng.jsp, last accessed September 2010). In addition, prolonged infusions more recently promoted to improve the PD of time-dependent antibiotics in the practice setting were studied. Of note, the standard recommended dose of ceftobiprole included 2 h infusions while the high dose of 1 g every 8 h [infusion time (t ′ ) 4 h] was under investigation at the time of this study [NIH, ClinicalTrials.gov at http://clinicaltrials.gov/ ct2/home (NCT00770978), last accessed September 2010].
Population pharmacokinetic models were used to simulate individual serum concentration profiles for each antibiotic regimen in the 5000 subjects. Models were selected based on criteria best representing pharmacokinetic parameters and variances in patients with serious infections (Table 2) . 11 -14 As such, population pharmacokinetic studies involving larger numbers of infected patients with sufficient data to identify covariate relationships (e.g. body weight versus volume of distribution, CL CR versus drug clearance) were used whenever possible. All pharmacokinetic and serum concentration profiles generated by MCS were carefully examined for appropriateness, and further compared with other pharmacokinetic studies including those in ICU patients. 15 -18 Concentration data were converted into f fractions using Gaussian distributions of 0.93+0.02 for meropenem, 0.70+0.02 for piperacillin/tazobactam, 0.85+0.02 for cefepime and 0.85+0.02 for ceftobiprole as per the product monographs (http://webprod.hc-sc.gc.ca/dpd-bdpp/index-eng. jsp). Next the most relevant PD index for time-dependent agents, Zelenitsky et al.
% fT . MIC , was determined for each antibiotic regimen in the 5000 simulated subjects at each dilutional MIC (e.g. 0.25, 0.5, 1 mg/L and so on). The probability of achieving targets of .50% fT . MIC , .75% fT . MIC and 100% fT . MIC was investigated. The probability of target attainment (PTA) for each antibiotic regimen at each MIC was then calculated as the fraction of 5000 subjects achieving .50%, .75% and 100% fT . MIC . The overall or cumulative target attainment (CTA), also reported as a fraction of the population, was determined by integrating each PTA with the corresponding pathogen and MIC distributions from Canadian ICU surveillance data. Identification and MIC data for 4798 bacterial isolates from ICU patients with infection were obtained from the Canadian National Intensive Care Unit (CANICU) and CANWARD studies conducted by the Canadian Antimicrobial Resistance Alliance (CARA) from 2005 to 2008, inclusive. 19 -22 The most common organisms were methicillin-susceptible S. aureus (MSSA) (20.1%), Escherichia coli (15.2%) and Pseudomonas aeruginosa (12.3%) followed by Klebsiella spp. (10.1%), Enterococcus spp. (8.1%), Haemophilus influenzae (8.0%), Streptococcus pneumoniae (7.4%), MRSA (6.5%), Enterobacter spp. (6.1%), Stenotrophomonas maltophilia (3.1%) and Serratia marcescens (3.1%). Approximately 60% of isolates were from male patients; 53.3% were from the respiratory tract, 25.7% from blood and 10.5% from each of urine and wound specimens. MICs were measured using microdilution methods as described by the CLSI. 20 -22 The CTA representing the overall PD performance of each antibiotic regimen was calculated by multiplying the PTA at each MIC by the fraction of isolates in that MIC category as per the surveillance data, and summing the values. The CTA excluding MRSA was also calculated for comparison since only ceftobiprole is intrinsically active against this pathogen. The CTA was compared between antibiotics, and non-standard strategies using prolonged infusions and/or highest recommended doses were compared with the standard 1 g every 8 h (t ′ 0.5 h) for meropenem, 3.375 g every 6 h (t ′ 0.5 h) for piperacillin/tazobactam, 2 g every 12 h (t ′ 0.5 h) for cefepime and 500 mg every 8 h (t ′ 2 h) for ceftobiprole. Absolute differences in CTA of ≤0.05 (i.e. ≤5%) were defined as minimal, 0.06 -0.10 (i.e. 6%-10%) as moderate, 0.11-0.20 (i.e. 11%-20%) as significant and .0.20 (i.e. .20%) as very significant. Figure S1 (available as Supplementary data at JAC Online). The % fT . MIC density plot for the same regimen is depicted in Figure 1 where individual % fT . MIC and hence CTA fall as the MIC increases.
Results
MCS
Empirical CTA data are summarized in Table 3 . With standard doses, ceftobiprole (500 mg every 8 h, t ′ 2 h) had 0.90 CTA at the .50% fT . MIC target while other agents exceeded the threshold in 0.79-0.82 of the population. When MRSA was excluded, CTA with standard doses of all antibiotics ranged from 0.84 to 0.89. CTA fell significantly at the higher targets of .75% and 100% fT . MIC . CTA at the highest threshold was 0.76, 0.62 and 0.62 with standard doses of ceftobiprole (500 mg every 8 h, t ′ 2 h), meropenem (1 g every 8 h, t ′ 0.5 h) and cefepime (2 g every 12 h, t ′ 0.5 h), respectively. Piperacillin/tazobactam (3.375 g every 6 h, t ′ 0.5 h) showed the greatest decline with only 0.36 of the population achieving 100% fT . MIC . When MRSA was excluded, CTA at the highest target fell slightly to 0.75 for ceftobiprole, and increased to 0.66 for meropenem and cefepime and to 0.39 for piperacillin/tazobactam.
Compared with standard doses, prolonged infusions and highdose regimens had minimal effect on attainment of .50% fT . MIC with more impact on achievement of the higher targets (Table 3) . Prolonged infusions of meropenem produced significant effects at the 100% fT .MIC target whereas increasing the dose produced moderate benefit. Prolonged infusions of piperacillin/tazobactam were especially advantageous producing significant to very significant increases in CTA at the .75% and 100% fT . MIC targets, respectively. Increasing the dose alone was largely ineffective at improving the PD of piperacillin/tazobactam. Overall, prolonged infusions of cefepime had less impact than shortening the dosing interval to 8 h, which produced moderate and significant increases in CTA at the .75% and 100% fT . MIC targets, respectively. Finally, increasing the ceftobiprole dose to the investigational 1 g every 8 h (t ′ 4 h) had minimal effect on attainment of .50% or .75% fT . MIC , but significant impact on achievement of 100% fT . MIC .
Target attainment at the .75% fT . MIC threshold against the most common pathogens is summarized in Table 4 . CTA against MSSA was .0.90 with standard doses of meropenem and ceftobiprole, prolonged infusions of piperacillin/tazobactam and prolonged infusions or high doses of cefepime. CTA against E. coli also exceeded 0.90 with standard doses of meropenem, cefepime and ceftobiprole, whereas prolonged infusions of piperacillin/tazobactam were required to maintain comparable PD. CTA was relatively low for all antibiotic regimens against the less susceptible P. aeruginosa. With standard doses, cefepime had the highest CTA (0.81) at the .50% fT . MIC target followed by meropenem (0.76), ceftobiprole (0.71) and piperacillin/tazobactam Overall the non-standard dosing strategies were most beneficial against P. aeruginosa with the ability to produce very significant increases in CTA. Prolonged infusions of high-dose cefepime (2 g every 8 h, t ′ 3 h) had the highest target attainment achieving .50%, .75% and 100% fT . MIC in 0.94, 0.88 and 0.79 of the population, respectively. Prolonged infusions of high-dose meropenem (2 g every 8 h, t ′ 3 h) and high-dose ceftobiprole were similar with 0.88-0.89 achieving .50% fT . MIC , 0.79 achieving .75% fT . MIC and 0.64-0.65 achieving 100% fT . MIC . Prolonged infusions of high-dose piperacillin/tazobactam (4.5 g 
Discussion
Our study analysed empirical antibiotic monotherapies for serious infections consistent with an ICU patient population. By using MCS, complex models of in vivo antibiotic PD and possible clinical implications can be extrapolated to the practice setting. In this case, meropenem, piperacillin/tazobactam and cefepime as potential empirical monotherapies used in Canadian ICUs were tested along with ceftobiprole, a novel extended-spectrum cephalosporin. A major strength of our study was the inclusion of national surveillance data for almost 4800 bacterial pathogens with infection profiles and MIC data consistent with the ICU setting.
Antibiotic MCS studies often use % fT . MIC targets, based primarily on in vitro and animal data, exceeding 20% for carbapenems, 30% for penicillins and 40% for cephalosporins for bacteriostasis; and 40%, 50% -60% and 60% -70%, respectively, for bactericidal effect. 2 Even so, there is mounting evidence that higher thresholds are associated with further clinical benefit, especially in the seriously ill. A study by Li et al. 23 of meropenem for lower respiratory tract infections found higher bacterial eradication rates when fT . MIC exceeded 54%, and improved clinical and microbiological outcomes when fC min /MIC exceeded 5. In another analysis of meropenem in patients with febrile neutropenia, Ariano et al. 24 reported a significantly higher cure rate of 83% compared with 59% when regimens achieved at least 75% fT . MIC . For cefepime, a recent trial by Crandon et al. 25 of patients with P. aeruginosa infection showed significantly better microbiological response when fT . MIC exceeded 60%. Other investigations of cefepime in patients with sepsis by McKinnon et al. 26 and Gram-negative infections by Tam et al. 18 found improved clinical cure and microbiological eradication rates when fT . MIC reached 100%. Given these data for higher than conventional % fT . MIC targets especially in patients with serious infections and the lack of clinical evidence for consistently different thresholds between classes, our study examined multiple targets of .50%, .75% and 100% fT . MIC . The inclusion of higher thresholds also enhanced the analysis by providing CTA profiles that were more discriminating and revealing of potential differences between regimens.
The appropriate interpretation of antibiotic MCS results is important. Most investigations define CTA ≥0.90 as acceptable with predictions that PD targets would be achieved in at least 90% of the population. It is notable when comparing results, however, that CTA is target dependent with higher probabilities of achieving lower thresholds. Furthermore, the value of statistical analyses in MCS studies is somewhat limited by the ability to simulate exceedingly large numbers of subjects. As a result, our study presented classifications based on proposed clinical relevance where differences in CTA of ≤0.05 were minimal, 0.06-0.10 were moderate, 0.11-0.20 were significant and .0.20 were very significant.
As the only agent active against MRSA, ceftobiprole demonstrated the highest overall empirical coverage achieving 0.90 CTA at the .50% fT . MIC target. When MRSA, representing 6.5% of all isolates in this study, was excluded, CTA was more comparable between agents (0.84 -0.89). A similar effect may be achieved by adding empirical anti-MRSA coverage with an agent such as vancomycin or linezolid to meropenem, piperacillin/tazobactam or cefepime. Although standard-dose ceftobiprole (500 mg every 8 h, t ′ 2 h) performed well as empirical monotherapy, its activity against P. aeruginosa was significantly lower. Ceftobiprole showed the greatest difference in CTA from 0.90 for empirical coverage to 0.71 against P. aeruginosa at the .50% fT . MIC target. Increasing the ceftobiprole dose to the investigational 1 g every 8 h (t ′ 4 h) restored the CTA to 0.89. Such findings from MCS can provide valuable pre-clinical data characterizing PD target attainment for new agents such as ceftobiprole in specific patient populations of interest. Interestingly, one clinical study of standard-dose ceftobiprole compared with ceftazidime plus linezolid for nosocomial pneumonia reported lower cure rates with ceftobiprole in patients with ventilatorassociated pneumonia. 27 Further analysis showed the largest differences between treatment groups in younger patients and those with high baseline CL CR . Given the dose, patient characteristics and pathogen profile, MCS can be used to explain or even predict potentially inferior regimens by quantifying the combined effects on PD target attainment (e.g. critical illness, young age, high baseline renal function, less susceptible pathogens). MCS can supplement pharmacokinetic, PD and clinical investigations in further determining the role of new agents such as ceftobiprole in treating special, high-risk populations such as the young, seriously ill.
As empirical antibiotic monotherapy (when excluding MRSA), standard doses of meropenem, piperacillin/tazobactam and cefepime achieved similar CTA (0.84 -0.88) at the .50% fT . MIC target with more aggressive doses providing little benefit. Prolonged infusions or high doses of meropenem and cefepime achieved .75% fT . MIC in at least 0.82 of the population, whereas piperacillin/tazobactam required prolonged infusions to maintain such coverage. Importantly, high-dose piperacillin/ tazobactam without prolonged infusions was largely ineffective at improving PD activity. The most aggressive doses of meropenem and cefepime reached 100% fT . MIC in 0.82 and 0.86 of the population, respectively, whereas piperacillin/tazobactam had 0.72 CTA.
Cefepime was most active against P. aeruginosa, but required dosing at 8 h intervals to achieve reasonable target attainment in our analysis. This is consistent with Bhat et al. 28 who found higher mortality rates in patients treated with cefepime for Gram-negative bacteraemia and pathogen MIC ≥8 mg/L. The authors concluded that cefepime dosing at 12 h intervals is inadequate for the treatment of P. aeruginosa given the current CLSI susceptibility breakpoint (i.e. MIC≤ 8 mg/L). Also consistent with other reports, 29 aggressive doses of meropenem, especially prolonged infusions, significantly improved our target attainment against P. aeruginosa. Finally, piperacillin/tazobactam was considerably less likely to achieve PD targets against P. aeruginosa although prolonged infusions improved our target attainment considerably. Similar questions regarding the use of piperacillin/ tazobactam for treating P. aeruginosa infections have been raised by others. Tam et al. 30 found higher mortality rates in patients with P. aeruginosa bacteraemia and reduced susceptibility to piperacillin/tazobactam defined as MIC¼32 or 64 mg/L, Antibiotic pharmacodynamics using Monte Carlo simulation 347 JAC but still reported susceptible according to the CSLI susceptibility breakpoint (i.e. MIC≤ 64 mg/L). Furthermore, a study by Lodise et al. 31 showed improved patient outcomes including survival in those with P. aeruginosa infection and APACHE II score ≥17 who were treated with piperacillin/tazobactam using extended versus standard infusion times. Although the product monograph recommends high-dose piperacillin/tazobactam in combination with an aminoglycoside for P. aeruginosa pneumonia, our findings seriously question the benefit of increasing the dose without prolonging the infusions and the rationale for only addressing respiratory tract infections. Given the poor antibiotic PD against P. aeruginosa overall, the most aggressive antibiotic doses along with combination therapy should be seriously considered.
Some important limitations of our study are inherent in MCS methods that use simulated patient cohorts. In addition, our findings were based on simulated antibiotic serum concentrations derived from population pharmacokinetic models. The pharmacokinetics of meropenem, 12 piperacillin/tazobactam 11 and cefepime 14 represented patients with serious infections such as complicated intra-abdominal infections and healthcare-associated pneumonia, but not necessarily the critically ill with sepsis and extraordinary alterations in antibiotic pharmacokinetics. Importantly, the only population model for ceftobiprole available at the time of our study was developed in a mixed sample of normal volunteers and infected patients. 13 Therefore, our ceftobiprole results warrant corroboration using pharmacokinetic models, when available, derived solely from those with serious infections. Our study focused on monotherapies using recommended doses with and without prolonged infusions. It did not address combination therapies commonly used in the ICU setting or investigational (off-label) strategies for optimizing PD such as higher-than-recommended doses or continuous infusions. Our analyses were also limited to subjects with normal renal function and did not include those with renal dysfunction or glomerular hyperfiltration with elevated CL CR and drug clearance as described in some critically ill patients. 32 -34 Finally, there are important limitations and cautions in extrapolating our findings to settings or regions not represented by the Canadian ICU surveillance where, for example, 24% of S. aureus were methicillin resistant, 6.5% of all isolates were MRSA and ,5% of E. coli and Klebsiella spp. produced extended-spectrum b-lactamase enzymes.
This study provides important comparative data on empirical antibiotic monotherapies in an ICU setting including preliminary data on ceftobiprole. Ceftobiprole was most active overall, but similar to meropenem, piperacillin/tazobactam (lowest target only) and cefepime when MRSA was excluded. Standard doses of all agents achieved .50% fT . MIC in at least 0.79 of the population; however, more aggressive dosing strategies using prolonged infusions and/or high doses were required to achieve .0.9 CTA, to reach higher targets or to cover less susceptible pathogens such as P. aeruginosa.
